托西利祖马布用于囊性黄斑,这是视网膜色素炎的次要原因
Stéphane Abramowicz1,2, Prochore Kamgang Semeu3, Isabelle Nubourgh4
1Department of Ophthalmology, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium. stephane.abramowicz@outlook.com.
Journal of ophthalmic inflammation and infection
|September 30, 2024
概括
托西利祖马布 (TCZ) 有效地减少了视网膜色素炎 (RP) 中的囊状黄斑 (CME) 和视网膜血管泄漏 (RVL). 这种静脉注射治疗对治疗RP患者的炎症并发症有前途.
科学领域:
- 眼科医生 眼科 眼科
- 类风湿病学 类风湿病学
- 遗传学 遗传学 是一个
背景情况:
- 视网膜色素炎 (RP) 可以呈现炎症特征,如囊性黄斑胀 (CME) 和视网膜血管泄漏 (RVL).
- 在RP中治疗这些炎症并发症的标准治疗通常会产生部分或不一致的反应.
研究的目的:
- 评估托西利祖马布 (TCZ) 在治疗与视网膜色素炎 (RP) 相关的CME和RVL的疗效.
主要方法:
- 两名RP患者的回顾性病例系列分析.
- 患者最初接受了皮质类固醇和各种疾病修饰性抗风湿药物 (DMARDs).
- 对于持续的炎症特征,治疗被切换为静脉注射 (IV) 托西利祖马布 (TCZ).
主要成果:
- 两位患者在开始IV TCZ后,CME和RVL的显著减少.
- 最初的诊断是具有挑战性的,在通过辅助测试和遗传分析确认RP之前,怀疑后膜炎.
- 第1名患者被诊断患有EYS相关的自体逆行性RP;第2名患者的基因检测呈阴性.
结论:
- 静脉注射托西利祖马布 (TCZ) 似乎是一种可行的治疗选择,用于在视网膜色素炎 (RP) 中管理CME和RVL.
- 需要进一步的研究来确定TCZ是否会影响RP的长期预后,特别是在慢性黄斑损伤导致的视力丧失方面.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Open Angle Glaucoma: Treatment
403
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
403
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


